Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotechnology company, announced the pricing of an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The offering is expected to close on February 27, 2026, with proceeds to be used for development of nomlabofusp and general corporate purposes. J.P. Morgan and Guggenheim Securities are serving as joint bookrunning managers.

02/25/2026, 8:59 PM • Benzinga

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics priced an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to support development of nomlabofusp for Friedreich's ataxia and for general corporate purposes. The offering is expected to close on February 27, 2026, with J.P. Morgan and Guggenheim Securities as joint bookrunning managers.

02/25/2026, 8:59 PM • GlobeNewswire

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.

10/16/2025, 4:44 AM • Benzinga

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR

DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.

10/15/2025, 9:30 PM • Benzinga

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating potential securities law violations by Larimar Therapeutics after the company reported study data with severe allergic reactions, causing a significant stock price drop.

10/15/2025, 9:09 PM • Benzinga

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Larimar Therapeutics reported allergic reactions in a pivotal study for nomlabofusp, a treatment for Friedreich's ataxia. Seven participants experienced anaphylaxis, leading to study modifications and stock price decline.

09/29/2025, 11:20 AM • Benzinga

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

Larimar Therapeutics reported positive results from its ongoing study of nomlabofusp, a potential treatment for Friedreich's Ataxia, showing increased frataxin levels and potential clinical improvements, despite experiencing some anaphylaxis events.

09/29/2025, 7:00 AM • GlobeNewswire

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

Larimar Therapeutics will host a conference call to discuss updates on its nomlabofusp clinical development program for treating Friedreich's ataxia, sharing data from an ongoing long-term open label study.

09/28/2025, 5:00 PM • GlobeNewswire

Larimar Beats Q2 Loss Estimates

Larimar Therapeutics, a clinical-stage biotech firm, reported Q2 2025 results with a narrower net loss of $0.41 per share. The company continues developing nomlabofusp for Friedreich's ataxia, with ongoing clinical trials and FDA engagement for potential accelerated approval in 2026.

08/14/2025, 7:33 AM • The Motley Fool

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Larimar Therapeutics completed a public offering of 21,562,500 common stock shares at $3.20 per share, raising $69.0 million to support drug development and corporate operations.

07/31/2025, 4:15 PM • Benzinga

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

Larimar Therapeutics plans to raise $60 million through a public offering of 18,750,000 common stock shares at $3.20 per share, with proceeds intended to support drug development and corporate operations.

07/29/2025, 11:50 PM • GlobeNewswire

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Larimar Therapeutics is conducting a public offering of common stock and pre-funded warrants to raise funds for developing treatments for rare diseases, specifically focusing on its lead compound nomlabofusp for Friedreich's ataxia.

07/29/2025, 4:01 PM • Benzinga